DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-2.66%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.09B
AUM Growth
+$3.09B
(+16%)
Cap. Flow
+$741M
Cap. Flow
% of AUM
24.01%
Top 10 Holdings %
Top 10 Hldgs %
53.08%
Holding
78
New
16
Increased
25
Reduced
8
Closed
8
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$96.7M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$79.4M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$76.2M |
| 4 |
Akero Therapeutics
AKRO
|
$69.6M |
| 5 |
BridgeBio Pharma
BBIO
|
$68.5M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$125M |
| 2 |
Harmony Biosciences
HRMY
|
$49.9M |
| 3 |
Neumora Therapeutics
NMRA
|
$42.4M |
| 4 |
Genmab
GMAB
|
$41.7M |
| 5 |
Guardant Health
GH
|
$41.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
RAPT Therapeutics
RAPT
$187M
| $7.33M | 0.24% |
6,011,380
| – | – |
|
52
Pliant Therapeutics
PLRX
$105M
| $7.29M | 0.24% |
5,399,681
-572,576
| -10% | -$773K |
|
53
Avalo Therapeutics
AVTX
$139M
| $6.89M | 0.22% |
859,876
-7,124
| -0.8% | -$57.1K |
|
|
BCYC
54
Bicycle Therapeutics
BCYC
$492M
| $6.51M | 0.21% |
767,016
-509,065
| -40% | -$4.32M |
|
55
Beam Therapeutics
BEAM
$1.9B
| $6.17M | 0.2% |
+315,765
| New | +$6.17M |
|
56
Invivyd
IVVD
$218M
| $5.88M | 0.19% |
9,722,254
-967,349
| -9% | -$586K |
|
57
Xencor
XNCR
$594M
| $5.85M | 0.19% |
549,439
+49,439
| +10% | +$526K |
|
|
RGLS
58
DELISTED
Regulus Therapeutics
RGLS
| $5.71M | 0.18% |
3,262,564
| – | – |
|
59
Inovio Pharmaceuticals
INO
$144M
| $5.08M | 0.16% |
3,119,162
| – | – |
|
|
RAPP
60
Rapport Therapeutics
RAPP
$549M
| $4.59M | 0.15% |
+457,556
| New | +$4.59M |
|
61
Context Therapeutics
CNTX
$75.6M
| $4.54M | 0.15% |
7,419,355
| – | – |
|
62
Zura Bio
ZURA
$132M
| $4.24M | 0.14% |
3,283,783
| – | – |
|
63
Aligos Therapeutics
ALGS
$75.1M
| $3.66M | 0.12% |
444,110
+200,000
| +82% | +$1.65M |
|
64
Spyre Therapeutics
SYRE
$1.02B
| $3.53M | 0.11% |
219,015
| – | – |
|
|
IMA
65
ImageneBio, Inc. Common Stock
IMA
$153M
| $3.22M | 0.1% |
+2,515,513
| New | +$3.22M |
|
|
OKUR
66
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $2.25M | 0.07% |
523,989
| – | – |
|
|
ALLK
67
DELISTED
Allakos
ALLK
| $1.65M | 0.05% |
7,232,701
+1,528,419
| +27% | +$348K |
|
68
Neurogene
NGNE
$284M
| $1.37M | 0.04% |
+116,660
| New | +$1.37M |
|
|
CLYM
69
Climb Bio, Inc. Common Stock
CLYM
$165M
| $1.27M | 0.04% |
1,040,115
| – | – |
|
|
VRNA
70
Verona Pharma
VRNA
$9.18B
| – | – |
-850,000
| Closed | -$39.5M |
|
|
SWTX
71
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-3,460,756
| Closed | -$125M |
|
72
Cassava Sciences
SAVA
$107M
| – | – |
0
| – | – |
|
|
73
Neumora Therapeutics
NMRA
$283M
| – | – |
-4,000,000
| Closed | -$42.4M |
|
74
Nektar Therapeutics
NKTR
$543M
| – | – |
-1,975,998
| Closed | -$1.84M |
|
|
CNTA
75
Centessa Pharmaceuticals
CNTA
$2.13B
| – | – |
-1,350,000
| Closed | -$22.6M |
|